Tech Transfer

Insulin delivery technology developed at UVA and commercialized by TypeZero Technologies, Inc. received initial support from UVA's Licensing and Ventures Group (LVG).

The UVA Licensing & Ventures Group (LVG) has invested in three Charlottesville-based ventures that grew out of University research. TypeZero Technologies Inc., TearSolutions Inc., and Mission Secure Inc.

NSF funding will allow UVA Engineering’s Link Lab to develop a new program that will train graduate students to make discoveries and then translate that knowledge into new technologies, products and services.

Professor Gregory B. Fairchild is the first director of Northern Virginia operations for the University of Virginia.

Plans are underway to create ease of connection between UVA's Research Park, CHO, and the Hollymead Town Center to benefit Virginia visitors and businesses.

The University has approved an academic affiliation with INOVA Health System and George Mason University.

The CvilleBioHub has been awarded over $80,000 from the GO Virginia initiative to expand and sustain the biotechnology ecosystem in the region.

UVA and UVA-Wise are considering recommendations for improving challenges faced by rural Virginians. The initiative is engaging additional Virginia colleges and universities, government agencies, and stakeholders across the state.

The UVA Research Park is a 562-acre park that provides state-of-the-art facilities to develop the creation and enhancement of research and business collaboration between the University and the public and private sectors — all for the economic and s

Industry clusters are groups of firms that gain a competitive advantage by co-locating in a geographic region and sharing assets, networks, knowledge, workforce training, etc. The Office of Economic Development partners with allies to help support…

UVA was named a National Science Foundation I-Corps Site—one of 89 such sites at universities in the nation—to help entrepreneurs consider customer feedback in developing ideas that are relevant to society and exhibit applications for commerciali

UVA licenses technology to Type Zero so that diabetes research can transition to the marketplace and create local jobs.